97353471 - ULTRAGENYX GENE THERAPY

Information

• Trademark
• 97353471

• Source

• Serial Number

  97353471

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  April 08, 2022
  2 years ago

• Transaction Date

  March 31, 2023
  a year ago

• Status Date

  March 31, 2023
  a year ago

• Location Date

  March 31, 2023
  a year ago

• Status Code

  602

• Current Location

  TMO LAW OFFICE 116 - EXAMINING ATTORNEY ASSIGNED

  Employee Name

  SWAIN, MICHELE LYNN

• Attorney Docket Number

  315613-20000

  Attorney Name

  Anne H. Peck

  Law Office Assigned Location Code

  M70

• Owners

  • ULTRAGENYX PHARMACEUTICAL INC.

Case File Statements

• DM0000: The mark consists of the word "ultragenyx" in lower case letters above the words "gene therapy". The formative "ultra" and the words "gene therapy" are purple and the formative "genyx" is green. The letter "x" in "genyx" is stylized and features an enlongated stroke reaching above and below the word "ultragenyx". A gray hexagon is below the formative "ultra" and to the left of the words "gene therapy." A double helix, one strand of which is purple and one strand of which is green, is vertically oriented inside the gray hexagon.
• GS0051: Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, and hematologic diseases and disorders
• CC0000: Color is not claimed as a feature of the mark.
• GS0011: Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapy
• GS0441: Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders
• GS0421: Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays

Case File Event Statements

• 3/31/2023 - a year ago

  10 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2

• 3/31/2023 - a year ago

  9 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2

• 3/31/2023 - a year ago

  8 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2

• 12/14/2022 - a year ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 12/14/2022 - a year ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 12/14/2022 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 12/12/2022 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 4/13/2022 - 2 years ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 4/12/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 4/12/2022 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP